Corrigendum: Clinical characteristics, renal involvement, and therapeutic options of pediatric patients with Fabry disease

Muntean, Carmen; Starcea, Iuliana Magdalena; Stoica, Cristina; Banescu, Claudia

doi:10.3389/fped.2022.1045199

CORRECTION article

Front. Pediatr. , 19 October 2022

Sec. Pediatric Nephrology

Volume 10 - 2022 | https://doi.org/10.3389/fped.2022.1045199

Corrigendum: Clinical characteristics, renal involvement, and therapeutic options of pediatric patients with Fabry disease

This article is a correction to:

Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients With Fabry Disease
1. Read original article

$\r\nCarmen Muntean &#x;$ Carmen Muntean^1*^†

Iuliana Magdalena Starcea^2,†

Cristina Stoica³ $Claudia Banescu\r\n$ Claudia Banescu⁴

¹Department of Pediatrics I, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania
²Department of Pediatric Nephrology, Sf Maria Emergency Hospital for Children Iasi, University of Medicine and Pharmacy Grigore T. Popa Iasi, Iasi, Romania
³Pediatric Nephrology Department, Fundeni Clinical Institute, University of Medicine and Pharmacy Carol Davila Bucharest, Bucharest, Romania
⁴Center for Advanced Medical and Pharmaceutical Research, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania

A corrigendum on

Clinical characteristics, renal involvement, and therapeutic options of pediatric patients with Fabry disease

By Muntean C, Starcea IM, Stoica C, Banescu C. (2022) Front Pediatr. 10: 908657. doi: 10.3389/fped.2022.908657

In the published article, authors mistakenly omitted the Funding statement. The Funding statement appears below.

Funding

“This was partly supported by a project financed by the Romanian Ministry of Education and Research, CNCS—UEFISCDI, project no PN-III-P4-ID-PCE-2020-1928, within the PNCDI III, contract no. PCE 72/2021”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: Fabry, kidney, GLA gene, biomarker, therapy

Citation: Muntean C, Starcea IM, Stoica C and Banescu C (2022) Corrigendum: Clinical characteristics, renal involvement, and therapeutic options of pediatric patients with Fabry disease. Front. Pediatr. 10:1045199. doi: 10.3389/fped.2022.1045199

Received: 15 September 2022; Accepted: 16 September 2022;
Published: 19 October 2022.

Edited by:

Frontiers in Pediatrics, Frontiers Media SA, Switzerland

© 2022 Muntean, Starcea, Stoica and Banescu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Carmen Muntean ZHVpY3VjYXJtZW5AeWFob28uY29t

^†These authors have contributed equally to this work

Specialty Section: This article was submitted to Pediatric Nephrology, a section of the journal Frontiers in Pediatrics

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Corrigendum: Clinical characteristics, renal involvement, and therapeutic options of pediatric patients with Fabry disease

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good